Clinical Activity of Selpercatinib in RET-mutant Pheochromocytoma.
Barbara Deschler-BaierBhavana KondaErminia MassarelliMimi I HuLori J WirthXiaojian XuJennifer WrightRoderick J Clifton-BlighPublished in: The Journal of clinical endocrinology and metabolism (2024)
These data support selpercatinib as an effective therapy against RET-mutant pheochromocytoma, adding to the diversity of RET-activated tumor types that may benefit from targeted RET inhibition.